Effects of behavioral activation therapy on some treatment parameters in breast cancer women

A clinical trial comparing the effects of behavioral activation therapy and no treatment on adherence to treatment, serum levels of tumor markers, nausea and vomiting during chemotherapy, and demoralization in breast cancer women

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017100817756N31

Enrollment

Registered

2017-11-10

Start date

2017-10-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer. Carcinoma in situ of breast, unspecified

Interventions

Intervention 1: Intervention Group (behavioral activation therapy): The intervention group will receive behavioral activation therapy in ten 120-minute sessions held one session per week. Intervention

Behavior

Intervention Group (behavioral activation therapy): The intervention group will receive behavioral activation therapy in ten 120-minute sessions held one session per week.

Control Group (No intervention): The control group will not receive any psychological intervention.

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Female patients over 18 years of age; breast cancer grade 2 or 3 confirmed by the oncologist; patient having undergone mastectomy; patient currently undergoing chemotherapy; simultaneous experience of demoralization along with breast cancer; lack of previous or concurrent participation in psychological interventions; no previous experience of behavioral activation intervention; chemotherapy-induced nausea and vomiting; non-compliance with treatment; completing the written consent form for participation in the psychological intervention. Exclusion criteria: Patient's death during Intervention; unwillingness to continue collaboration in the research; failure to do homework or exercises; and absence from intervention and treatment for 2 sessions or more.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Adherence to treatment. Timepoint: Before and after intervention. Method of measurement: Morisky Medication Adherence Scale.;Serum levels of cancer markers. Timepoint: Before and after intervention. Method of measurement: laboratory results.;Chemotherapy-induced nausea and vomiting. Timepoint: before and after intervention. Method of measurement: Index of Nausea, Vomiting, and Retching.;Demoralization. Timepoint: Before and after intervention. Method of measurement: Demoralization Scale by Kissane et al. (2004).	—

Measure

Time frame

Adherence to treatment. Timepoint: Before and after intervention. Method of measurement: Morisky Medication Adherence Scale.;Serum levels of cancer markers. Timepoint: Before and after intervention. Method of measurement: laboratory results.;Chemotherapy-induced nausea and vomiting. Timepoint: before and after intervention. Method of measurement: Index of Nausea, Vomiting, and Retching.;Demoralization. Timepoint: Before and after intervention. Method of measurement: Demoralization Scale by Kissane et al. (2004).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Zahra Farshidfar

Birjand University of Medical Sciences

z.farshidfar@yahoo.com+98 56 3239 5680

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026